Amivas (US), LLC is an Australian, Canadian, and US joint venture focused on the development, manufacturing, and commercialization of therapeutics for the treatment of infectious diseases.
Amivas (US), LLC was formed in response to the urgent need for a US -based firm to assume responsibility for the manufacture and distribution of Artesunate for Injection, for severe malaria after quinidine gluconate was discontinued by the manufacturer.
With FDA approval of its first commercial product, Amivas (US), LLC is proud to join the global effort to fight and eradicate malaria.
For more information about Amivas (US), LLC and Artesunate for Injection, please see our most recent press release.
Read about a new severe malaria product and how to order. This innovative malaria treatment is our first registered medication for slow bolus intravenous delivery. Artesunate for Injection is administered during hospitalization. It is suitable for the treatment of patients with severe malaria.